(Q36904844)

17 August 2017

1 reference

title

Novel protease and polymerase inhibitors for the treatment of hepatitis C virus infection (English)

1 reference

17 August 2017

1 reference

Julie Sheldon

1

0 references

Vicente Soriano

series ordinal

3

object named as

Vincent Soriano

1 reference

17 August 2017

Pablo Barreiro

2

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 August 2007

1 reference

Expert Opinion on Investigational Drugs

17 August 2017

published in

1 reference

17 August 2017

volume

16

1 reference

17 August 2017

issue

8

1 reference

17 August 2017

page(s)

1171-1181

1 reference

Treatment of chronic hepatitis C infection with peginterferons plus ribavirin

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1171

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1171

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1171

Replicon cell culture system as a valuable tool in antiviral drug discovery against hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1171

New therapeutic strategies for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1171

Hepatitis C: molecular virology and antiviral targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1171

The hepatitis C virus life cycle as a target for new antiviral therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1171

Nucleotide triphosphatase/helicase of hepatitis C virus as a target for antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1171

Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1171

Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1171

Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1171

VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1171

SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1171

Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1171

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1171

Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1171

Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1171

Structural Analysis of the Hepatitis C Virus RNA Polymerase in Complex with Ribonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1171

Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1171

Deoxycholic acid activates protein kinase C and phospholipase C via increased Ca2+ entry at plasma membrane.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1171

Ribavirin Antagonizes the In Vitro Anti-Hepatitis C Virus Activity of 2'-C-Methylcytidine, the Active Component of Valopicitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1171

The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1171

Adult onset type II citrullinemia as a cause of non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1171

Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1171

Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1171

In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1171

Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1171

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1171

Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1171

Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1171

Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1171

Core labeling of adenovirus with EGFP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1171

The culture of designing hepato-biliary randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1171

Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1171

10.1517/13543784.16.8.1171

21 January 2018

Identifiers

DOI

1 reference

release_4wxz4b5lkve47icg6lmoptchom

17 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4wxz4b5lkve47icg6lmoptchom

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference